VolitionRx has executed a non-binding Letter of Intent, or LOI, with Missionpharma A/S, a Danish global company in the filed of the sale and distribution of healthcare products and innovative solutions, regarding the potential development and launch of Volition's prototype Lateral Flow Technology, or LFT, for NETosis. Sepsis is a major contributor in settings such as LMICs, especially in Africa, which bears the greatest mortality burden.

9/10 08:30

VolitionRx Presents Early Cancer Detection Technology at ESMO Conference

VolitionRx announced the presentation of an abstract at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference - ESMO MAP - in London this week. The presentation highlights the use of its Capture-Seq technology in the detection of early-stage I solid cancer. Andrew Retter, Medical Consultant, Volition, said: "From a clinical perspective, the proof of concept and early blinded validation results reported are extremely encouraging. In two independent cohorts we reported no false positives and detected 49/49 cancers in the first cohort - including 23 early stage I/II and 21 healthy controls - and validated it in a second blinded cohort with 13/14 later stage cancers detected with 10 additional healthy controls. We also subsequently reported data from a blinded validation cohort of 81 subjects and the results are likewise very promising; the early-stage cancer detection of 95% of stage I and II cancers is particularly noteworthy. For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq could contribute to Multi-Cancer Early Detection fulfilling a significant unmet clinical need. We also believe that Capture-Seq has the potential to play a role in cancer management, including but not limited to, Minimal Residual Disease detection and treatment monitoring, either alone or potentially in combination with other technologies too."

8/28 16:30

Selling Stockholders Plan to Sell 10.01M Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholders of up to 10.01M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

8/26 08:30

VolitionRx Publishes Study on H3.1 Biomarker

VolitionRx announced the publication of a peer-reviewed paper and independent Editorial which reported that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy, or RRT, in sepsis and septic shock patients. Entitled "H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis-A Secondary Analysis of the SISPCT Randomized Control Trial1" and published in Critical Care Medicine, the findings demonstrate Nu.Q NETs H3.1 is a promising novel biomarker for early mortality and organ dysfunction in sepsis, with significantly higher levels found in septic shock than sepsis patients and a clear dose-response relationship with acute kidney injury severity. These findings indicate that Nu.Q NETs H3.1 has potential clinical utility for risk stratification and early intervention in critically ill patients presenting with sepsis. Sepsis carries a heavy social, economic and health burden worldwide; there were approximately 166 million cases worldwide resulting in 21.4 million deaths in 20217.

8/13 16:30

Volition CEO Says Tech Market Opportunities Exceed $27 Billion

CEO Cameron Reynolds said, "We have made strong progress across all of our product pillars throughout 2026 to date. We are currently in discussions, including undertaking technology evaluations, with more than a dozen of the world's leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue...We continue to add to our significant data rooms with published, submitted and confidential data across our product pillars. Most notably, we recently announced the publication of our first peer-reviewed paper demonstrating our breakthrough Capture-Seq liquid biopsy technology...The Total Addressable Markets for our technologies, on an annualized basis, are multi-billion-dollar opportunities (estimated at more than $27B across all of our product pillars), not only for Volition, but for our licensing partners. Volition has made strong progress, both clinically and commercially, and our technology is now poised to be used very widely in a broad range of clinical utilities."

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。

VNRX 資訊

VNRX 事件

相關文章